Belite Bio Inc's Tom Lin speaks with Proactive's Andrew Scott soon after its NASDAQ listing. The company's lead drug LBS-008 is a potent small molecule RBP4 antagonist that has been specifically designed to reduce the delivery of retinol to the eye as a therapeutic approach towards reducing the accumulation of cytotoxic bisretinoids - preserving the integrity of retinal tissues and ultimately slowing or preventing loss of vision.
Belite Bio to speed up development of its incurable blindness treatment following NASDAQ listing
